Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations

European Journal of Pharmacology

Volumn 303, Issue 3, 1996, Pages 187-192

  Liu, Yu J ^a   Jackson, Dale M ^a   Blackham, Alan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

antagonist affinity; BW A868C; BW245C; DP receptor; prostaglandin D2

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; GR 321916; INDOMETACIN; POTASSIUM CHLORIDE; PROSTAGLANDIN D2; PROSTAGLANDIN DP RECEPTOR; PROSTAGLANDIN DP RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VAPIPROST;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ANTAGONISM; DRUG SELECTIVITY; FEMALE; ISOLATED ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SAPHENOUS VEIN; SMOOTH MUSCLE RELAXATION; VEIN;

EID: 0029941771     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00037-4     Document Type: Article

References (14)

1. 2-receptor antagonists on the mouse isolated stomach assay, Br. J. Pharmacol. 86, 581.
2. Coleman, R.A., P.P.A. Humphrey, I. Kennedy and P. Lumley, 1982, Prostanoid receptors - the development of a working classification, Trends Pharmacol. Sci. 5, 303.
3. Giles, H., P. Leff, M.L. Bolofo, M.G. Kelly and A.D. Robertson, 1989, The classification of prostaglandin DP-receptor in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist, Br. J. Pharmacol. 96, 291.
4. Kennedy, I., R.A. Coleman, P.P.A. Humphrey, G.P. Levy and P. Lumley, 1982, Studies on the characterization of prostanoid receptors: a proposed classification, Prostaglandins 24, 667.
5. Liu, Y.J. and D.M. Jackson, 1995, Are there subtypes of prostaglandin DP receptors, Br. J. Pharmacol. 115, (Proc. Suppl.) 134P.
6. Lydford, S.J., K.C.W. Mckechnie and P. Leff, 1994, Interaction of BW A868C with two receptor-subtypes in the rabbit saphenous vein, in: Proceedings of the 9th International Conference on Prostaglandins and Related Compounds, p. 85.
7. Senior, J., R. Sangha, G.S. Baxter, K. Marshall and J.K. Clayton, 1992, In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium, Br. J. Pharmacol. 107, 215.
8. Senior. J., K. Marshall, R. Sangha and J.K. Clayton, 1993, In vitro characterization of prostanoid receptors on human myometrium at term pregnancy, Br. J. Pharmacol. 108, 501.
9. Smith, G.C.S., R.A. Coleman and J.C. Mcgrath, 1994, Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus, J. Pharmacol. Exp. Ther. 271(1), 390.
10. 2 values and associated analysis, J. Pharmacol. Exp. Ther. 207(3), 705.
11. 2 receptors, Prostaglandins 25, 13.
12. Waud, D.R. and R.B. Parker, 1971, Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. II. Competitive antagonists, J. Pharmacol. Exp. Ther. 177(1), 13.
13. Whittle, B.J.R., S. Moncada, K. Mullane and J.R. Vane, 1983, Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue, Prostaglandins 25, 205.
14. Woodward, D.F., C.S. Spada, S.B. Hawley, L.S. Williams, C.E. Protzman and A.L. Nieves, 1993, Further studies on ocular responses to DP receptor stimulation, Eur. J. Pharmacol. 230, 327.